Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 1228       
REVIEW ARTICLE
Year : 2013  |  Volume : 138  |  Issue : 4  |  Page : 449-460

New treatment strategies for Alzheimer's disease: is there a hope?


1 Laboratory of Neuroscience (LIM 27) Department & Institute of Psychiatry, Faculty of Medicine,University of São Paulo, Brazil
2 Laboratory of Neuroscience (LIM 27) Department & Institute of Psychiatry, Faculty of Medicine,University of São Paulo; UNESP, Biosciences Institute, Campus of Rio Claro-SP, Brazil

Correspondence Address:
Orestes V Forlenza
Laboratory of Neuroscience (LIM-27) Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Rua Dr. Ovídio Pires de Campos 785 05403-010 - São Paulo, SP
Brazil
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 24434253

Rights and PermissionsRights and Permissions

Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease, and corresponds to the most common cause of dementia worldwide. Although not fully understood, the pathophysiology of AD is largely represented by the neurotoxic events triggered by the beta-amyloid cascade and by cytoskeletal abnormalities subsequent to the hyperphosphorylation of microtubule-associated Tau protein in neurons. These processes lead respectively to the formation of neuritic plaques and neurofibrillary tangles, which are the pathological hallmarks of the disease. Clinical benefits of the available pharmacological treatment for AD with antidementia drugs (namely cholinesterase inhibitors and memantine) are unquestionable, although limited to a temporary, symptomatic support to cognitive and related functions. Over the past decade, substantial funding and research have been dedicated to the search and development of new pharmaceutical compounds with disease-modifying properties. The rationale of such approach is that by tackling key pathological processes in AD it may be possible to attenuate or even change its natural history. In the present review, we summarize the available evidence on the new therapeutic approaches that target amyloid and Tau pathology in AD, focusing on pharmaceutical compounds undergoing phase 2 and phase 3 randomized controlled trials.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2357    
    Printed23    
    Emailed0    
    PDF Downloaded813    
    Comments [Add]    

Recommend this journal